Brussels is back in full swing and so are the European Biomanufacturing Enterprises’ (EBE) Working Groups! Today, we are kicking off a new spotlight series featuring each of EBE’s working groups, starting with the one focusing on personalised medicine (PM), which will be meeting today.
The Personalised Medicine Working Group (PMWG), which is now a joint working group with EFPIA, advocates for a legislative environment that will ensure the right medicines are delivered to the right patients at the right time. Everyone is different and people with apparently the same clinical diagnosis or symptoms can have very different responses to the same treatment. It’s clear that a ‘one-size-fits-all’ approach is no longer sufficient and the personalised medicines that EBE members produce can vastly improve patients’ lives. Finding a way to provide these personalised treatments across Europe has been the mission of the working group since its creation in 2010.
Key representatives of the International Consortium for Personalised Medicine (ICPerMed) will attend the PMWG meeting today to learn more about a recently published EBE-EFPIA report on the benefits of personalised medicine to patients, society and healthcare systems and discuss potential synergies. In this report, EBE and EFPIA called on EU Member States to implement five new policy recommendations to advance personalised medicine from coherent prioritisation of personalised medicine within existing strategic health plans to collaborative actions for tackling current reimbursement delays.
The PMWG is also fostering an optimal implementation of the in vitro diagnostics regulation that was adopted in April last year. Quite a few challenges are raised by this new legislation linked to the performance evaluation of diagnostic tests or the delineation of responsibilities between key stakeholders. The PMWG is promoting the view of the pharmaceutical industry during its interactions with the European Commission, the EMA or Member States representatives.
The personalised medicines working group is one of five EBE working groups, including Advanced Therapies, Innovation and Funding, Biotherapeutics and Biomanufacturing – all of which offer companies a platform to communicate technical positions externally and shape public policy so that the biopharmaceutical industry can thrive.
Stay tuned for the next installment in our spotlight series!